Influence of Sedentary Time on Skeletal Muscle Protein Metabolism

Sedentary Lifestyle Clinical Trial

Official title:

Influence of Increased Sedentary Time on Long-term Rates of Skeletal Muscle Protein Synthesis in Young Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02624011
• Other study ID #: ERN_15-1238
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: February 2018

Study information

• Verified date: October 2018
• Source: University of Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the influence of increased sedentary time on long-term measures of muscle protein synthesis and metabolic health. The investigators will test the hypothesis that increased time spent in sedentary behaviours will lead to a reduction in long-term measures of muscle protein synthesis and compromised metabolic health.

Description:

Sarcopenia, the loss of muscle mass with age, is thought to be accelerated by an inactive, sedentary lifestyle. Increased sedentary time has consistently been associated with lower muscle mass and compromised metabolic health. However, there is currently a lack of direct evidence to support these associations.

Therefore, this study will investigate whether increased sedentary time (reduced step count and exercise cessation) directly influences long-term measures of muscle protein synthesis and metabolic health in young, active adults. Following a 7 day period of normal habitual physical activity, participants will undertake a 7 day period of step reduction and exercise cessation. It is hypothesised that 7 days of increased sedentary time will result in a reduction in long-term rates of muscle protein synthesis and a worsening of metabolic health.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: February 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Body mass index (18.5-29.99 kg/m2)

• Active - defined as: = 7000 steps per day (assessed during screening) and taking part in regular exercise (defined as participation in = 3 sessions of aerobic and/or resistance exercise type sessions a week for = 6 months prior to recruitment)

• Good general health

Exclusion Criteria:

• Lidocaine allergy

• Hypertension (=140/90 mmHg)

• Current participation in another clinical study

• Previous participation in this study

• Bleeding disorder/s

• Current or recent smoker

• Past history of substance abuse and/or taking prescription or non-prescription medication (e.g., beta-blockers, insulin or thyroxine) or supplements that may influence normal metabolic responses.

• Participants who have previously (within 5 years of the present study) had 4 or more muscle biopsies obtained from the thigh quadriceps region will be ineligible.

Related Conditions & MeSH terms

• Sedentary Lifestyle

Intervention

Behavioral:
• 7 days of habitual physical activity followed by 7 days of reduced physical activity
Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.

Locations

Country	Name	City	State
United Kingdom	School of Sport Exercise and Rehabilitation Sciences, University of Birmingham	Birmingham

Sponsors (2)

Lead Sponsor	Collaborator
University of Birmingham	Maastricht University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle protein synthesis (FSR %/day)	Long-term muscle protein synthesis (FSR %/day) will be determined using deuterium oxide (D2O) to compare muscle protein synthesis rates over the first 7 day period and the second 7 day period.	0-14 days
Secondary	Rate of fat oxidation at rest (g/min)	Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) at rest will be measured using indirect calorimetry to calculate the rate of fat oxidation at rest (g/min).	For 20 minutes at day 7 and day 14
Secondary	Rate of fat oxidation during an oral glucose tolerance test (g/min)	Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) following an oral glucose drink will be measured using indirect calorimetry to calculate the rate of fat oxidation during an oral glucose tolerance test (g/min).	At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14
Secondary	Rate of carbohydrate oxidation at rest (g/min)	Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) at rest will be measured using indirect calorimetry to calculate the rate of carbohydrate oxidation at rest (g/min).	For 20 minutes at day 7 and day 14
Secondary	Rate of carbohydrate oxidation during an oral glucose tolerance test (g/min)	Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) following an oral glucose drink will be measured using indirect calorimetry to calculate the rate of carbohydrate oxidation during an oral glucose tolerance test (g/min).	At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14
Secondary	Blood glucose concentration	Blood glucose concentration will be assessed in blood samples taken during the oral glucose tolerance test.	At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14
Secondary	Blood insulin concentration	Blood insulin concentration will be assessed in blood samples taken during the oral glucose tolerance test.	At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14
Secondary	Blood fatty acid concentration	Blood fatty acid concentration will be assessed in blood samples taken during the oral glucose tolerance test.	At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14